Blow To AZ As FDA Rejects COPD Contender
Executive Summary
Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.
You may also be interested in...
Nanopharm And Fluidda Join Forces To Speed Up Inhaled Drug Approvals
Nanopharm and Fluidda are collaborating on a computational approach for assessing bioequivalence in inhaled generics. Their project aims to ease the USFDA approvals process for a drug class whose pharmacokinetic properties are notoriously difficult to observe.
Can Glenmark’s Triple Therapy Combo Move COPD Treatment Needle?
Glenmark rolls out three-in-one inhaler therapy for COPD in India and hopes to address challenges faced by patients suffering from the severe form of the disease. Some early physician outlook appears mixed for the new combination in a segment where leading respiratory player Cipla has an established product.
GSK Puts Faith In Next Gen Respiratory, Real World Studies
A pioneer in the field, can GSK’s investment in real world studies pay off?